The IFRD1 Knockout A-549 Polyclonal Cells provide a heterogeneous population of A-549 human lung adenocarcinoma epithelial cells with CRISPR/Cas9-mediated disruption of the IFRD1 gene. This polyclonal knockout format delivers a pooled loss-of-function model, enabling comprehensive assessment of IFRD1 ablation within an epithelial context without the bias of clonal isolation. The cells are produced via CRISPR/Cas9 gene editing to inactivate the transcriptional coregulator IFRD1.
The A-549 host cell line was isolated from the lung adenocarcinoma of a 58-year-old Caucasian male and grows as adherent epithelial-like cells. A-549 is a standard model for lung adenocarcinoma biology, epithelial barrier function, and pulmonary disease research, including studies of cystic fibrosis modifier genes and chronic obstructive pulmonary disease. These cells are widely employed for investigating epithelial responses to inflammatory cytokines.
IFRD1 functions as a transcriptional coregulator that modulates chromatin structure and gene expression by recruiting histone deacetylases HDAC1/2 and SWI/SNF components SMARCA4/SMARCB1 to target promoters. It is activated by interferon-gamma, TGFB1, and IL4, and intersects with Notch signaling through interactions with NOTCH1, RBPJ, and MAML1. Downstream, IFRD1 regulates myogenic differentiation factors MEF2C and MYOD, cytokine IL3, and chromatin remodeling complexes, positioning it at a node of inflammatory, developmental, and proliferative signaling.
In A-549 lung adenocarcinoma cells, IFRD1 knockout enables dissection of pathways critical for tumor cell differentiation, interferon responsiveness, and inflammatory regulation. This model is particularly relevant for studying Notch-driven epithelial plasticity, STAT1/JAK1/TYK2-dependent interferon signaling, and the contributions of IFRD1 to cystic fibrosis and COPD modifier networks. The heterogeneous knockout population mirrors tumor microenvironment diversity, offering advantages for drug response screening.
Key applications include interferon-gamma stimulation assays to probe STAT1 activation, RT-qPCR and western blotting for target gene and protein analysis (e.g., MEF2C, MYOD, IL3), ChIP-qPCR to assess HDAC recruitment, and Notch reporter assays. Additional uses encompass cell proliferation, migration, and invasion assays, and transcriptome-wide RNA-seq. For further product information, technical data, or assistance with experimental design, please contact Ascent Research.
